-
6m 14sPart 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
9m 23sPart 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
7m 21sPart 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
-
16m 1sPart 3 | Session 11 Dr Reddy & Dr Nair on CHAMPION-AF: Redefining Stroke Prevention
-
7m 26sPart 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
5m 34sPart 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
4m 5sPart 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
5m 18sPart 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
3m 7sPart 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
5m 8sPart 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
2m 21sPart 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
10m 19s
-
25m 1sPart 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
18m 33sPart 1 | Session 2 ALERT: Under-treatment in AS and MR
-
26m 37sPart 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
19m 43sPart 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
6m 44sPart 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
9m 4sPart 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
-
5m 51sPart 3 | Session 1 Door to Unload Randomized Clinical Trial
-
5m 58sPart 3 | Session 2 ALL-RISE – Coronary Physiology From Angiography vs Pressure Wire for PCI
-
6m 28s
-
8m 35sPart 3 | Session 4 The STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion in STEMI
-
4m 47s
-
13m 52sPart 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes for complex heart failure patients.
Drawing on his experience as a leading heart failure pharmacologist and past President of the International Society of Cardiovascular Pharmacotherapy (ISCP), Prof. Martínez offers practical guidance on how cardiology teams can integrate ACC.26 evidence into day‑to‑day prescribing and team‑based care.
This interview is produced in collaboration with the International Society of Cardiovascular Pharmacotherapy (ISCP) and European Cardiology Review (ECR).
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Felipe Martínez
Emeritus Professor of Medicine - Cordoba National University
Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina
Fellow of the European Society of Cardiology (FESC)
Fellow of the American College of Cardiology (FACC)
Past President - International Society of Cardiovascular Pharmacology
Dr Felipe Martínez is on the Editorial Board of European Cardiology Review.
Comments